NEW YORK (360Dx) – Shares of Laboratory Corporation of America were down 11 percent in morning trading today following the company's announcement that it was lowering its full-year 2018 guidance on the top and bottom lines.

Total revenue growth is expected to be in the range of 9.9 percent to 10.3 percent year over year, down from prior guidance of 10.5 percent to 11 percent growth. Revenue growth for LabCorp Diagnostics is expected to be in the range of 2.1 percent to 2.5 percent, down from prior guidance of 3 percent to 3.5 percent.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Sponsored by
Advanced Cell Diagnostics

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease. 


In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.

Sponsored by

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.